Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.

Journal of viral hepatitis - 1 Jan 2019

Lampertico Pietro, Brunetto Maurizia R, Craxì Antonio, Gaeta Giovanni B, Rizzetto Mario, Rozzi Antonella, Colombo Massimo

Abstract excerpt

Nucleos(t)ide analogues (NAs) and peginterferon have complementary effects in chronic hepatitis B, but it is unclear whether combination therapy improves responses in genotype D-infected patients. We conducted an open-label study of peginterferon alfa-2a 180 μg/wk added to ongoing NA therapy in hepatitis B e antigen (HBeAg)-negative, genotype D-infected patients with hepatitis B virus DNA <20 IU/mL. The primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Interferon-alpha

Share to Nucleosides

Share to Polyethylene Glycols

Source

Identifiers

PMID: 30187599
DOI: 10.1111/jvh.12999

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.PMID 30187599Read ↗

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis BSemantic proximity Read ↗

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy.Semantic proximity Read ↗

Current developments in nucleoside/nucleotide analogues for hepatitis B.Semantic proximity Read ↗

Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.Semantic proximity Read ↗

Investigational RNA Interference Agents for Hepatitis BSemantic proximity Read ↗

Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferonSemantic proximity Read ↗

Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.Semantic proximity Read ↗

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.Semantic proximity Read ↗

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B InfectionSemantic proximity Read ↗

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.Semantic proximity Read ↗

Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis.Semantic proximity Read ↗

Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.